← ANALYST RATINGS · TIPRANKS
Boston Scientific (BSX): analyst forecast and price target
Analyst consensus
Strong Buy13 Buy3 Hold0 Sell
Ratings of 16 analysts in the last 3 months · top analysts only12-month forecast
Based on 16 price targets given in the last 3 months, the average target is $56.13, the highest $66.00, the lowest $48.00. The average is +26.5% from the last price of $44.39.
Analyst ratings 30
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Richard Newitter★★★★★★★★★★#1772 · hits 48% · avg +6.6% | Truist Financial | $57.00 → $51.00−10.5% | Buy | +14.9% | Reiterated | 14.10.26on TipRanks 22:25 | +2.4%next day +1.7% | ↗ |
| Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% | Piper Sandler | $60.00 | Buy | +35.2% | Reiterated | 14.10.26on TipRanks 07:25 | +0.4%next day +2.4% | ↗ |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $60.00 → $55.00−8.3% | Buy | +23.9% | Assigned | 13.10.26on TipRanks 07:35 | −1.2%next day +0.4% | ↗ |
| Marie Thibault★★★★★★★★★★#12343 · hits 40% · avg −9.7% | BTIG | $56.00 | Buy | +26.2% | Reiterated | 12.10.26on TipRanks 09:45 | +2.7%next day −1.2% | ↗ |
| Mike Kratky★★★★★★★★★★#1691 · hits 46% · avg +12.9% | Leerink Partners | $60.00 → $55.00−8.3% | Buy | +23.9% | Assigned | 12.10.26on TipRanks 07:35 | +2.7%next day −1.2% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $47.00 → $46.00−2.1% | Hold | +3.6% | Downgrade | 07.10.26on TipRanks 10:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $46.00 → $45.00−2.2% | Hold | +1.4% | Reiterated | 07.10.26on TipRanks 10:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $47.00 → $46.00−2.1% | Buy | +3.6% | Reiterated | 07.10.26on TipRanks 10:05 | — | |
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $48.00 | Hold | +8.1% | Initiated | 07.10.26on TipRanks 03:55 | −1.2%next day +1.5% · 5 days +4.4% | ↗ |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $47.00 → $46.00−2.1% | Hold | +3.6% | Downgrade | 06.10.26on TipRanks 16:05 | — | |
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | $48.00 | Hold | +8.1% | Assigned | 05.10.26on TipRanks 07:12 | −1.1%next day −1.0% · 5 days +3.0% | ↗ |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $46.00 → $45.00−2.2% | Hold | +1.4% | Downgrade | 03.10.26on TipRanks 02:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $47.00 → $46.00−2.1% | Hold | +3.6% | Downgrade | 03.10.26on TipRanks 02:05 | — | |
| Unknown Analyst | Bernstein | $60.00 → $54.00−10.0% | Buy | +21.6% | Assigned | 02.10.26on TipRanks Oct 4 05:05 | −2.2%next day −1.1% · 5 days −0.9% | ↗ |
| Name not given | — | $70.00 | Buy | +57.7% | Reiterated | 01.10.26on TipRanks Oct 2 21:45 | −1.1%next day −2.2% · 5 days −4.1% | ↗ |
| Robbie Marcus★★★★★★★★★★#1974 · hits 51% · avg +6.5% | J.P. Morgan | $56.00 | Buy | +26.2% | Reiterated | 01.10.26on TipRanks 12:36 | −1.1%next day −2.2% · 5 days −4.1% | ↗ |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $50.00 → $48.00−4.0% | Hold | +8.1% | Assigned | 24.09.26on TipRanks Sep 23 16:45 | +0.2%next day −2.2% · 5 days −2.8% | ↗ |
| Suraj Kalia★★★★★★★★★★#1646 · hits 50% · avg +6.8% | Oppenheimer | $85.00 → $65.00−23.5% | Buy | +46.4% | Assigned | 21.09.26on TipRanks 07:45 | −0.7%next day +2.8% · 5 days +1.9% | ↗ |
| Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% | Bank of America Securities | $54.00 | Buy | +21.6% | Reiterated | 20.09.26on TipRanks Sep 21 06:10 | −0.7%next day +2.8% · 5 days +1.9% | ↗ |
| Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% | TD Cowen | $56.00 | Buy | +26.2% | Reiterated | 17.09.26on TipRanks Sep 18 02:20 | −2.0%next day −0.6% · 5 days +1.7% | ↗ |
| Matthew Taylor★★★★★★★★★★#1367 · hits 55% · avg +7.2% | Jefferies | $60.00 | Buy | +35.2% | Reiterated | 11.09.26on TipRanks 10:26 | −1.1%next day +5.3% · 5 days +0.9% | ↗ |
| David Toung★★★★★★★★★★#1098 · hits 63% · avg +9.1% | Argus Research | — | Hold | — | Downgrade | 30.07.26on TipRanks Jul 31 07:27 | −1.8%next day +0.9% · 5 days +3.6% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $65.00 → $55.00−15.4% | Buy | +23.9% | Reiterated | 30.07.26on TipRanks 08:45 | −1.8%next day +0.9% · 5 days +3.6% | ↗ |
| Pito Chickering★★★★★★★★★★#1500 · hits 61% · avg +9.8% | Deutsche Bank | $75.00 → $60.00−20.0% | Buy | +35.2% | Reiterated | 30.07.26on TipRanks 08:31 | −1.8%next day +0.9% · 5 days +3.6% | ↗ |
| David Rescott★★★★★★★★★★#3448 · hits 49% · avg +5.1% | Robert W. Baird | $64.00 → $56.00−12.5% | Buy | +26.2% | Reiterated | 30.07.26on TipRanks 08:00 | −1.8%next day +0.9% · 5 days +3.6% | ↗ |
| William Plovanic★★★★★★★★★★#5377 · hits 43% · avg +1.3% | Canaccord Genuity | $70.00 → $66.00−5.7% | Buy | +48.7% | Reiterated | 30.07.26on TipRanks 07:15 | −1.8%next day +0.9% · 5 days +3.6% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $74.00 → $67.00−9.5% | Buy | +50.9% | Reiterated | 30.07.26on TipRanks Jul 28 08:17 | +1.0%next day +1.5% · 5 days +2.5% | ↗ |
| Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% | Needham | $57.00 | Buy | +28.4% | Reiterated | 29.07.26on TipRanks 14:53 | +1.5%next day −1.8% · 5 days −1.8% | ↗ |
| Rick Wise★★★★★★★★★★#7800 · hits 51% · avg +0.1% | Stifel Nicolaus | $65.00 → $60.00−7.7% | Buy | +35.2% | Reiterated | 29.07.26on TipRanks Jul 28 08:15 | +1.0%next day +1.5% · 5 days +2.5% | ↗ |
| David Roman★★★★★★★★★★#3715 · hits 53% · avg +5.3% | Goldman Sachs | $71.00 → $57.00−19.7% | Buy | +28.4% | Reiterated | 14.07.26on TipRanks Jul 15 16:35 | −4.9%next day +0.6% · 5 days +1.8% | ↗ |
| Michael Polark★★★★★★★★★★#2909 · hits 51% · avg +6.5% | Wolfe Research | — | Hold | — | Downgrade | 29.05.26on TipRanks 05:45 | −1.9%next day −1.0% · 5 days +3.0% | ↗ |
| Christopher Pasquale★★★★★★★★★★#1776 · hits 61% · avg +11.9% | Nephron | $85.00 | Buy | +91.5% | Upgrade | 23.04.26on TipRanks 07:20 | +1.7%next day −6.3% · 5 days −13.7% | ↗ |
| Hans Engel★★★★★★★★★★#1835 · hits 58% · avg +11.1% | Erste Group | — | Hold | — | Assigned | 01.04.26on TipRanks Apr 2 10:00 | −1.9%next day +1.2% · 5 days −4.9% | ↗ |
| Jayson Bedford★★★★★★★★★★#819 · hits 60% · avg +8.6% | Raymond James | $97.00 → $88.00−9.3% | Buy | +98.2% | Reiterated | 27.03.26on TipRanks Mar 30 05:10 | +0.3%next day −8.7% · 5 days −13.4% | ↗ |
| Lee Hambright★★★★★★★★★★#10167 · hits 49% · avg −1.6% | Bernstein | $130 → $112−13.8% | Buy | +152.3% | Reiterated | 05.02.26on TipRanks Feb 6 07:35 | +4.1%next day −3.7% · 5 days −5.1% | ↗ |
| Unknown Analyst | CTBC Securities | $122 | Buy | +174.8% | Initiated | 13.01.26on TipRanks Jan 15 13:15 | −1.5%next day +0.1% · 5 days −1.4% | |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Boston Scientific
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $58.58 at a price of $43.65 (+34.2%); now: $57.14 at $44.39 (+28.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 23 | 16 | 11 | 5 | 4 | 0 |
| Buy | 38 | 32 | 34 | 29 | 30 | 17 |
| Hold | 3 | 3 | 4 | 2 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 28.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.75 (from $0.58 to $0.84). Last quarter: $0.86.
Sales
Next quarter’s sales estimate — $5.1B (from $4.7B to $5.3B). Last quarter: $5.4B.
Best top-analyst consensus in the sector · Healthcare
About Boston Scientific
- CEO: Michael F. Mahoney
- Employees: 59,000
- 300 Boston Scientific Way, Marlborough, MA, 01752-1234, US
- www.bostonscientific.com
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thro
Data from the stock’s TipRanks forecast page, read 0 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗